Tokyo, April 7 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000061166) titled 'A Fundamental Study of Brain Representation Mechanisms Using fNIRS: Insight... Read More
Tokyo, April 7 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000061170) titled 'Effects of AI-based advice on sleep debt reduction' on April 7. Study Type... Read More
Tokyo, April 7 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000061174) titled 'Effect of a single intake of the test food on premenstrual syndrome (PMS) s... Read More
Tokyo, April 7 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000061175) titled 'Effect of continuous intake of the test food on premenstrual syndrome (PMS)... Read More
Singapore, April 6 -- The Health Sciences Authority received information related to the study titled ''Establishing the role of mitomycin C and systemic non-steroidal anti-inflammatory drugs in the po... Read More
Singapore, April 6 -- The Health Sciences Authority received information related to the study titled 'IZABRIGHT-Lung01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507... Read More
Singapore, April 6 -- The Health Sciences Authority received information related to the study titled 'ROSETTA CRC-203: A Blinded, Randomized Phase 2/3 Study of Pumitamig in Combination with Chemothera... Read More
Singapore, April 6 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safet... Read More
Singapore, April 6 -- The Health Sciences Authority received information related to the study titled 'A Phase III, Randomized, Open-Label, Multicenter, Global Study of Puxitatug Samrotecan (AZD8205) M... Read More
Singapore, April 6 -- The Health Sciences Authority received information related to the study titled 'DAREON®-Lung 1: A Phase III multi-center, open-label, randomised trial of intravenous obrixtamig i... Read More